The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer

Donal J. Brennan; Sara Ek; Emma Doyle; Thomas Drew; Michael Foley; Grainne Flannelly; Darran P. O'Connor; William M. Gallagher; Sami Kilpinen; Olli-Pekka Kallioniemi; Karin Jirstrom; Colm O'Herlihy; Carl A. K. Borrebaeck

doi:10.1016/j.ejca.2009.01.028

The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer

Donal J. Brennan
, Sara Ek
, Emma Doyle
, Thomas Drew
, Michael Foley
, Grainne Flannelly
, Darran P. O'Connor
, William M. Gallagher
, Sami Kilpinen
, Olli-Pekka Kallioniemi
, Karin Jirstrom
, Colm O'Herlihy
, Carl A. K. Borrebaeck^*

^*Corresponding author for this work

VTT Technical Research Centre of Finland

Research output: Contribution to journal › Article › Scientific › peer-review

73 Citations (Scopus)

Abstract

Background
Current prognostic molecular markers for epithelial ovarian cancer (EOC) are insufficient. The aim of the current study was to investigate the role of Sox11 in EOC.

Methods
Using an in silico transcriptomic screen, Sox11 was identified as a potential EOC biomarker. Sox11 protein expression was evaluated using immunohistochemistry (IHC) in 76 EOC cases, which were analysed using automated algorithms to develop a quantitative scoring model.

Results
Sox11 mRNA expression was upregulated in EOC compared to normal tissues. Automated analysis of Sox11 in the EOC cohort revealed high expression of Sox11, in 40% of tumours, who had an improved recurrence-free survival (RFS) (p = 0.002). Multivariate analysis confirmed that Sox11 was an independent predictor of improved RFS after controlling for stage and grade.

Conclusions
These data suggest that Sox11 is a new prognostic marker in EOC. Loss of Sox11 is associated with a decreased RFS and a more aggressive phenotype.

Original language	English
Pages (from-to)	1510-1517
Journal	European Journal of Cancer
Volume	45
Issue number	8
DOIs	https://doi.org/10.1016/j.ejca.2009.01.028
Publication status	Published - 2009
MoE publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Sox11
Epithelial ovarian cancer
Prognosis
Automated analysis

Access to Document

10.1016/j.ejca.2009.01.028

Cite this

Brennan, D. J., Ek, S., Doyle, E., Drew, T., Foley, M., Flannelly, G., O'Connor, D. P., Gallagher, W. M., Kilpinen, S., Kallioniemi, O.-P., Jirstrom, K., O'Herlihy, C., & Borrebaeck, C. A. K. (2009). The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. European Journal of Cancer, 45(8), 1510-1517. https://doi.org/10.1016/j.ejca.2009.01.028

@article{50e06412a5fc47daa6096f8946ef131a,

title = "The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer",

abstract = "Background Current prognostic molecular markers for epithelial ovarian cancer (EOC) are insufficient. The aim of the current study was to investigate the role of Sox11 in EOC.Methods Using an in silico transcriptomic screen, Sox11 was identified as a potential EOC biomarker. Sox11 protein expression was evaluated using immunohistochemistry (IHC) in 76 EOC cases, which were analysed using automated algorithms to develop a quantitative scoring model.Results Sox11 mRNA expression was upregulated in EOC compared to normal tissues. Automated analysis of Sox11 in the EOC cohort revealed high expression of Sox11, in 40\% of tumours, who had an improved recurrence-free survival (RFS) (p = 0.002). Multivariate analysis confirmed that Sox11 was an independent predictor of improved RFS after controlling for stage and grade.Conclusions These data suggest that Sox11 is a new prognostic marker in EOC. Loss of Sox11 is associated with a decreased RFS and a more aggressive phenotype.",

keywords = "Sox11, Epithelial ovarian cancer, Prognosis, Automated analysis",

author = "Brennan, \{Donal J.\} and Sara Ek and Emma Doyle and Thomas Drew and Michael Foley and Grainne Flannelly and O'Connor, \{Darran P.\} and Gallagher, \{William M.\} and Sami Kilpinen and Olli-Pekka Kallioniemi and Karin Jirstrom and Colm O'Herlihy and Borrebaeck, \{Carl A. K.\}",

year = "2009",

doi = "10.1016/j.ejca.2009.01.028",

language = "English",

volume = "45",

pages = "1510--1517",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier",

number = "8",

}

Brennan, DJ, Ek, S, Doyle, E, Drew, T, Foley, M, Flannelly, G, O'Connor, DP, Gallagher, WM, Kilpinen, S, Kallioniemi, O-P, Jirstrom, K, O'Herlihy, C & Borrebaeck, CAK 2009, 'The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer', European Journal of Cancer, vol. 45, no. 8, pp. 1510-1517. https://doi.org/10.1016/j.ejca.2009.01.028

TY - JOUR

T1 - The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer

AU - Brennan, Donal J.

AU - Ek, Sara

AU - Doyle, Emma

AU - Drew, Thomas

AU - Foley, Michael

AU - Flannelly, Grainne

AU - O'Connor, Darran P.

AU - Gallagher, William M.

AU - Kilpinen, Sami

AU - Kallioniemi, Olli-Pekka

AU - Jirstrom, Karin

AU - O'Herlihy, Colm

AU - Borrebaeck, Carl A. K.

PY - 2009

Y1 - 2009

N2 - Background Current prognostic molecular markers for epithelial ovarian cancer (EOC) are insufficient. The aim of the current study was to investigate the role of Sox11 in EOC.Methods Using an in silico transcriptomic screen, Sox11 was identified as a potential EOC biomarker. Sox11 protein expression was evaluated using immunohistochemistry (IHC) in 76 EOC cases, which were analysed using automated algorithms to develop a quantitative scoring model.Results Sox11 mRNA expression was upregulated in EOC compared to normal tissues. Automated analysis of Sox11 in the EOC cohort revealed high expression of Sox11, in 40% of tumours, who had an improved recurrence-free survival (RFS) (p = 0.002). Multivariate analysis confirmed that Sox11 was an independent predictor of improved RFS after controlling for stage and grade.Conclusions These data suggest that Sox11 is a new prognostic marker in EOC. Loss of Sox11 is associated with a decreased RFS and a more aggressive phenotype.

AB - Background Current prognostic molecular markers for epithelial ovarian cancer (EOC) are insufficient. The aim of the current study was to investigate the role of Sox11 in EOC.Methods Using an in silico transcriptomic screen, Sox11 was identified as a potential EOC biomarker. Sox11 protein expression was evaluated using immunohistochemistry (IHC) in 76 EOC cases, which were analysed using automated algorithms to develop a quantitative scoring model.Results Sox11 mRNA expression was upregulated in EOC compared to normal tissues. Automated analysis of Sox11 in the EOC cohort revealed high expression of Sox11, in 40% of tumours, who had an improved recurrence-free survival (RFS) (p = 0.002). Multivariate analysis confirmed that Sox11 was an independent predictor of improved RFS after controlling for stage and grade.Conclusions These data suggest that Sox11 is a new prognostic marker in EOC. Loss of Sox11 is associated with a decreased RFS and a more aggressive phenotype.

KW - Sox11

KW - Epithelial ovarian cancer

KW - Prognosis

KW - Automated analysis

U2 - 10.1016/j.ejca.2009.01.028

DO - 10.1016/j.ejca.2009.01.028

M3 - Article

SN - 0959-8049

VL - 45

SP - 1510

EP - 1517

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 8

ER -

The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this